Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tosedostat with Cytarabine or Decitabine in AML/MDS
NCT01567059Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- May 2012
- Primary completion
- Jun 2013
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tosedostat in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Proportion of patients achieving Complete Remission at 4 months and 4 Month Survival Rate. Started May 2012; status: completed.
02
Drugs
tosedostat
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01567059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01567059.